Thermo Fisher Scientific, Inc.

Equities

TMO

US8835561023

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 04:00:02 2026-02-10 pm EST			5-day change	1st Jan Change
539.80 ^USD	-1.27%		-7.21%	-6.84%

Feb. 10	Thermo Fisher Scientific Prices $3.8 Billion Senior Notes	MT
Feb. 10	Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes	CI

Health Care Down on Health-Insurance Concerns -- Health Care Roundup

Published on 01/12/2026 at 05:56 pm EST

Dow Jones

THERMO FISHER SCIENTIFIC, INC.

-1.27%

UNITEDHEALTH GROUP INC.

-0.90%

CENTENE CORPORATION

+4.13%

Health-care companies ticked down as regulators continued to probe the health-insurance industry.

UnitedHealth Group shares fell after a Senate committee found the largest U.S. health insurer by enrollees deployed aggressive tactics to collect payment-boosting diagnoses for its Medicare Advantage members. Rivals such as Centene and Humana fell in sympathy.

Thermo Fisher Scientific's number-two executive, Michel Lagarde, is leaving the life-sciences giant to pursue another opportunity.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

01-12-26 1755ET

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
THERMO FISHER SCIENTIFIC, INC.	539.80USD	-1.27%	-7.21%	205B
UNITEDHEALTH GROUP INC.	273.22USD	-0.90%	-4.33%	250B
CENTENE CORPORATION	39.61USD	+4.13%	-7.45%	18.71B

Latest news about Thermo Fisher Scientific, Inc.

Feb. 10	Thermo Fisher Scientific Prices $3.8 Billion Senior Notes	MT
Feb. 10	Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes	CI
Feb. 09	Thermo Fisher Scientific says prices $3.8 bln offering of USD-denominated senior notes	RE
Feb. 09	Thermo Fisher Scientific files pricing term sheet for $3.8 billion four part senior notes offering	RE
Feb. 09	Thermo Fisher Scientific Inc files for four-part senior notes offering size not disclosed	RE
Feb. 05	Microsoft-Backed OpenAI Launches Frontier Platform to Manage Enterprise AI Agents	MT
Feb. 05	IQVIA forecasts weak annual profit on higher interest expenses	RE
Feb. 05	IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer	CI
Feb. 04	Biotech firm Bio-Techne beats quarterly estimates on strength in key unit	RE
Feb. 02	Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter	RE
Jan. 30	UBS Adjusts Price Target on Thermo Fisher Scientific to $615 From $590, Maintains Neutral Rating	MT
Jan. 30	Raymond James Adjusts Price Target on Thermo Fisher Scientific to $670 From $630, Maintains Outperform Rating	MT
Jan. 30	Baird Adjusts Price Target on Thermo Fisher Scientific to $653 From $645, Maintains Outperform Rating	MT
Jan. 30	Barclays Adjusts Price Target on Thermo Fisher Scientific to $650 From $625, Maintains Overweight Rating	MT
Jan. 30	JPMorgan Adjusts Price Target on Thermo Fisher Scientific to $710 From $675, Maintains Overweight Rating	MT
Jan. 30	Deutsche Bank Adjusts PT on Thermo Fisher Scientific to $665 From $620, Maintains Buy Rating	MT
Jan. 30	Citigroup Adjusts Price Target on Thermo Fisher Scientific to $685 From $660, Maintains Buy Rating	MT
Jan. 30	TD Cowen Adjusts Price Target on Thermo Fisher Scientific to $683 From $696, Maintains Buy Rating	MT
Jan. 30	Rothschild & Co Redburn Adjusts PT on Thermo Fisher Scientific to $620 From $575, Maintains Buy Rating	MT
Jan. 29	Thermo Fisher forecasts 2026 profit below estimates on research funding cuts	RE
Jan. 29	Baird Lifts Thermo Fisher Scientific Price Target to $653 From $645	MT
Jan. 29	JPMorgan Raises Thermo Fisher Scientific Price Target to $710 From $675	MT
Jan. 29	Sector Update: Health Care Stocks Decline Thursday Afternoon	MT
Jan. 29	Thermo Fisher beats quarterly results estimates on demand for tools from pharma clients	RE
Jan. 29	Thermo Fisher Scientific Inc., Q4 2025 Earnings Call, Jan 29, 2026

Chart Thermo Fisher Scientific, Inc.

Duration

Period

TMO: Dynamic Chart

Company Profile

Thermo Fisher Scientific Inc. specializes in the design, manufacturing and marketing of laboratory and scientific equipments. Net sales (including intragroup) break down by family of products as follows: - laboratory equipments (73.2%). Moreover, the group proposes chemical products (reagents, solvent, salts, etc.), consumable products (tubes, funnels, vials, etc.), as well as conditioning, warehousing, storage, etc.; - scientific analysis equipments (16.7%): analyzer (of water, gas, grounds, etc.), mass spectrometers, molecular spectroscopes, microscopes, manometers, samplers, microbiology equipments, reactive agents, etc.; - diagnostics equipment and products (10.1%). Net sales break down by source of revenue between sales of products (58.4%) and services (41.6%). Net sales break down geographically as follows: North America (52.5%), Europe (25.3%), Asia/Pacific (18.6%) and other (3.6%).

Employees

125,000

Sector

Advanced Medical Equipment & Technology

Calendar

Apr. 28 - Q1 2026 Earnings Release (Projected)

More about the company